Ruxolitinib Intermediates: Key Components in Advanced API Manufacturing
The pharmaceutical industry is constantly evolving, with targeted therapies playing a pivotal role in treating complex diseases. Ruxolitinib, a potent Janus kinase (JAK1/JAK2) inhibitor, is widely used for treating myelofibrosis, polycythemia vera, and other chronic inflammatory disorders. To ensure the consistent quality and effectiveness of this drug, the availability of high-purity Ruxolitinib intermediates is essential. […]
Continue Reading